Abbott Laboratories Q1 Earnings Call Highlights

• AbbVie’s Prognosis: The February Dip Looks Like a Buy Signal

Ford said the Exact Sciences acquisition “adds a caller high-growth concern to the Abbott portfolio,” strengthening Abbott’s diagnostics enactment and expanding into crab diagnostics. He reiterated Abbott’s anticipation that Exact Sciences volition adhd astir $3 cardinal of incremental income successful 2026 and accelerate Abbott’s semipermanent income maturation rate.

CFO Phil Boudreau said first-quarter reported results see Exact Sciences from the adjacent day done quarter-end, but Abbott is present emphasizing comparable income growth metrics that see Exact Sciences income successful some the anterior and current-year periods. “To align with our reporting of comparable income growth, our afloat twelvemonth 2026 income maturation outlook of 6.5%–7.5% is present connected a comparable ground arsenic well,” Boudreau said.

→ GPU Prices Are Surging—3 Ways to Play the AI Chip Shortage

• Is Abbott’s January Pullback a Good Time to Buy?

Boudreau besides updated net expectations to bespeak the acquisition’s impact. Compared with the anterior full-year adjusted EPS guidance midpoint of $5.68, the caller midpoint of $5.48 reflects $0.20 of dilution related to the Exact Sciences deal, which helium said was accordant with assumptions astatine the clip the transaction was announced.

On a comparable basis, Abbott’s first-quarter income accrued 3.7%, and adjusted EPS roseate 6% twelvemonth implicit year, Boudreau said. Foreign speech provided a favorable year-over-year interaction of 4% connected first-quarter sales, reflecting U.S. dollar weakness earlier successful the quarter.

→ This New ETF Aims to Capitalize connected Surging AI Memory Chip Demand

Ford outlined show crossed large segments:

• Diagnostics: Core Lab Diagnostics income accrued 2% connected a comparable basis, driven by 3% maturation crossed the U.S., Europe, and Latin America. Core Lab trial volumes (excluding superior instrumentality and integer solutions) accrued twelvemonth implicit twelvemonth and sequentially, a inclination Ford said helium expects to proceed and enactment higher maturation successful the 2nd half. Rapid and molecular diagnostics income declined 10% owed to little respiratory microorganism investigating request amid a “much weaker respiratory season.”

• Cancer diagnostics: Sales grew 13% connected a comparable basis, driven by “mid-teens” maturation of Cologuard and “high teens” maturation successful planetary markets, Ford said.

• Nutrition: Sales finished “slightly ahead” of expectations, with results reflecting little volumes versus the anterior twelvemonth and the interaction of strategical pricing actions taken successful the 4th fourth of 2025 to re-accelerate measurement growth. Ford said aboriginal information indicates the intended effect, with measurement maturation “beginning to travel our pricing actions.”

• Established Pharmaceuticals (EPD): Sales accrued 9% with broad-based growth, including double-digit gains successful respective countries crossed Latin America and Asia Pacific.

• Medical devices: Sales grew 8.5%, led by cardiovascular devices, including double-digit maturation successful electrophysiology, bosom failure, and bushed management.